Synopsis Neoadjuvant therapy (NAT) for pancreatic adenocarcinoma (PDAC) ensures systemic treatment, avoids unnecessary surgery, and is associated with a higher rate of negative margin and lymph node involvement. Early trials have shown a benefit with NAT by increasing median survival and higher resectability rates. The present study aims to present the clinical outcomes of gemcitabine and erlotinib followed by gemcitabine plus radiotherapy and concomitant erlotinib in patients with resectable PDAC. This week’s “ MED FACT ” discusses a multicenter, phase II trial from Journal of Clinical Oncology, “ Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine–erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial) ”.
Authors: J. Maurel, et. al. Key Takeaways Treatment with Neoadjuvant Chemotherapy results in long-term Disease-free…
